Chemed Corp. (NYSE:CHE) to Release Earnings on Tuesday
Chemed Corp. (NYSE:CHE) is set to announce its earnings results after the market closes on Tuesday, July 25th. Analysts expect the company to announce earnings of $1.89 per share for the quarter. Chemed Corp. has set its FY17 guidance at $7.80-$8.00 EPS.
Chemed Corp. (NYSE:CHE) last issued its quarterly earnings results on Wednesday, April 26th. The company reported $1.82 EPS for the quarter, beating analysts’ consensus estimates of $1.78 by $0.04. The company had revenue of $405.90 million for the quarter, compared to analyst estimates of $399.75 million. Chemed Corp. had a return on equity of 24.62% and a net margin of 7.14%. The company’s quarterly revenue was up 4.0% compared to the same quarter last year. During the same period last year, the company earned $1.62 earnings per share. On average, analysts expect Chemed Corp. to post $7.83 EPS for the current fiscal year and $8.51 EPS for the next fiscal year.
Chemed Corp. (CHE) opened at 205.75 on Tuesday. The firm has a market capitalization of $3.31 billion, a price-to-earnings ratio of 30.19 and a beta of 1.15. Chemed Corp. has a one year low of $130.05 and a one year high of $216.01. The stock’s 50 day moving average price is $204.60 and its 200-day moving average price is $183.85.
In other Chemed Corp. news, insider Kevin J. Mcnamara sold 4,000 shares of the business’s stock in a transaction on Tuesday, May 2nd. The stock was sold at an average price of $205.11, for a total value of $820,440.00. Following the transaction, the insider now owns 148,943 shares of the company’s stock, valued at $30,549,698.73. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Donald E. Saunders sold 400 shares of the business’s stock in a transaction on Wednesday, May 3rd. The stock was sold at an average price of $204.85, for a total value of $81,940.00. Following the completion of the transaction, the director now directly owns 9,886 shares in the company, valued at approximately $2,025,147.10. The disclosure for this sale can be found here. In the last three months, insiders sold 5,400 shares of company stock worth $1,104,850. Insiders own 5.32% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/07/18/chemed-corp-nyseche-to-release-earnings-on-tuesday.html.
CHE has been the topic of a number of recent analyst reports. Zacks Investment Research lowered Chemed Corp. from a “buy” rating to a “hold” rating in a research note on Tuesday, May 2nd. BidaskClub lowered Chemed Corp. from a “strong-buy” rating to a “buy” rating in a research note on Thursday, June 22nd. Finally, Royal Bank Of Canada reissued a “hold” rating and issued a $208.00 price objective on shares of Chemed Corp. in a research note on Wednesday, July 5th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $186.00.
About Chemed Corp.
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Receive News & Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related companies with MarketBeat.com's FREE daily email newsletter.